High dosages of mTOR inhibitors result in a significant reduction of 4E-BP1 phosphorylation and mTOR activity, all of which may be factors in ER stress, C/EBP homologous protein (CHOP), and death receptor 5 (DR5) and consequent cancer cell death. Here, DDIT3 is linked to cancer.